LYEL Stock Price, Lyell Immunopharma, Inc. Quote, Chart

Market Summary

USD2.53+0.13

Market Closed

5.42%

LYEL Stock Price

View Fullscreen

LYEL RSI Chart

LYEL Valuation

Market Cap

645.0M

Price/Earnings (Trailing)

-2.82

Price/Sales (Trailing)

5.0K

Price/Free Cashflow

-4.01

LYEL Price/Sales (Trailing)

LYEL Profitability

Return on Equity

-37.86%

Return on Assets

-32.89%

Free Cashflow Yield

-24.91%

LYEL Fundamentals

LYEL Revenue

Revenue (TTM)

130.0K

Rev. Growth (Yr)

-99.97%

Rev. Growth (Qtr)

-48%

LYEL Earnings

Earnings (TTM)

-228.3M

Earnings Growth (Yr)

9.4%

Earnings Growth (Qtr)

-14.62%

Breaking Down LYEL Revenue

Last 7 days

-0.4%

Last 30 days

-15.9%

Last 90 days

42.9%

Trailing 12 Months

-15.9%

How does LYEL drawdown profile look like?

LYEL Financial Health

Current Ratio

16.51

LYEL Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	63.5M	42.4M	21.3M	130.0K
2022	29.2M	47.7M	66.2M	84.7M
2021	8.9M	8.5M	10.0M	10.7M
2020	0	3.0M	5.4M	7.8M
2019	0	0	0	657.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lyell Immunopharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	lee gary k.	acquired	-	-	40,000	chief scientific officer
Feb 09, 2024	newton charles w.	acquired	-	-	40,000	chief financial officer
Feb 09, 2024	hill stephen j.	acquired	-	-	40,000	chief operating officer
Feb 09, 2024	lang matthew	acquired	-	-	50,000	chief business officer
Feb 09, 2024	seely lynn	acquired	-	-	200,000	president and ceo
Aug 15, 2023	klausner richard	sold	-132,286	2.28	-58,020	-
Sep 23, 2022	klausner richard	sold	-71,041	6.4001	-11,100	-
Sep 08, 2022	bishop hans edgar	acquired	14,538	0.1	145,380	-
Feb 23, 2022	bishop hans edgar	acquired	99,342	0.1	993,428	-
Dec 14, 2021	friedman cathy	acquired	-	-	218,722	-

Which funds bought or sold LYEL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	FRANKLIN RESOURCES INC	unchanged	-	24,132	185,569	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.85	23,377	190,719	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	2.02	1,319,680	8,958,880	-%
May 13, 2024	XPONANCE, INC.	added	3.79	3,851	23,794	-%
May 13, 2024	FMR LLC	reduced	-0.7	765,323	6,175,450	-%
May 13, 2024	UBS Group AG	reduced	-8.98	19,618	444,167	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-963,000	-	-%
May 13, 2024	Lighthouse Investment Partners, LLC	new	-	274,294	274,294	0.01%
May 13, 2024	Nuveen Asset Management, LLC	added	16.8	484,871	1,900,080	-%
May 13, 2024	XTX Topco Ltd	reduced	-28.75	-54,559	246,903	0.03%

Are Funds Buying or Selling LYEL?

Are funds buying LYEL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LYEL

No. of Funds

Unveiling Lyell Immunopharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	arch venture fund ix, l.p.	14.5%	36,412,716	SC 13G/A
Feb 13, 2024	vanguard group inc	5.40%	13,604,027	SC 13G/A
Jan 29, 2024	blackrock inc.	5.7%	14,302,220	SC 13G
Feb 13, 2023	foresite capital fund iv, l.p.	4.0%	1e+07	SC 13G/A
Feb 09, 2023	vanguard group inc	5.05%	12,591,230	SC 13G
Feb 14, 2022	mwg management ltd.	8.38%	20,162,332	SC 13G
Feb 14, 2022	newton (ptc) ltd	6.28%	15,093,969	SC 13G
Feb 14, 2022	arch venture fund ix, l.p.	15.1%	36,412,716	SC 13G
Feb 11, 2022	foresite capital fund iv, l.p.	5.5%	13,282,181	SC 13G

Recent SEC filings of Lyell Immunopharma, Inc.

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	424B5	Prospectus Filed
May 06, 2024	8-K	Current Report
May 03, 2024	EFFECT	EFFECT
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 29, 2024	S-3	S-3
Feb 28, 2024	10-K	Annual Report

Peers (Alternatives to Lyell Immunopharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Lyell Immunopharma, Inc. News

Latest updates

Lyell Immunopharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-100.0%	-	0.00	0.00	0.00	24.00	48.00	0.00	36.00	19.00	3.00	3.00	3.00	2.00	2.00	1.00	3.00	-
Operating Expenses	-6.6%	56.00	60.00	59.00	66.00	63.00	63.00	66.00	73.00	69.00	50.00	52.00	65.00	58.00	42.00	38.00	106	-
S&GA Expenses	-100.0%	-	13.00	16.00	19.00	19.00	26.00	26.00	30.00	34.00	32.00	21.00	19.00	17.00	15.00	14.00	10.00	-
R&D Expenses	-8.1%	43.00	47.00	44.00	47.00	45.00	38.00	42.00	44.00	36.00	19.00	31.00	46.00	42.00	35.00	25.00	97.00	-
Net Income	-14.6%	-60.67	-52.93	-50.85	-63.89	-66.96	-8.40	-70.25	-36.32	-68.14	-83.71	-48.87	-62.59	-55.04	-38.86	-35.72	-100	-
Net Income Margin	2.7%	0.00	0.00	-8.94*	-4.94*	-2.86*	-2.16*	-3.91*	-4.97*	-9.03*	-23.48*	-20.49*	-22.73*	-25.74*	-26.36*	-	-	-
Free Cashflow	-3.4%	-42.05	-40.66	-37.88	-40.09	-47.74	-44.85	-39.89	-51.50	-57.58	-43.48	-37.09	-58.39	-52.79	-51.61	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-7.4%	694	750	795	835	880	938	977	1,022	1,072	1,127	1,198	1,230	908
Current Assets	-3.7%	534	555	587	606	624	651	660	667	626	626	631	835	618
Cash Equivalents	-13.5%	126	146	286	224	109	124	116	206	223	294	394	564	141
Net PPE	-4.7%	98.00	103	108	114	119	123	126	128	126	120	116	110	77.00
Liabilities	-4.2%	91.00	95.00	97.00	98.00	97.00	104	157	154	191	198	212	208	190
Current Liabilities	-6.3%	32.00	35.00	35.00	34.00	31.00	37.00	51.00	50.00	41.00	47.00	59.00	64.00	49.00
Shareholder's Equity	-7.9%	603	655	698	737	784	833	820	868	881	930	986	1,022	-
Retained Earnings	-6.1%	-1,062	-1,002	-949	-898	-834	-767	-759	-688	-652	-584	-500	-451	-334
Additional Paid-In Capital	0.6%	1,666	1,657	1,648	1,638	1,622	1,608	1,589	1,565	1,540	1,516	1,487	1,474	41.00
Shares Outstanding	0.4%	255	254	252	251	250	250	248	246	244	136	101	43.00	-
Float	-	-	-	-	654	-	-	-	1,100	-	-	-	2,741	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-3.4%	-42,016	-40,635	-37,686	-39,161	-46,212	-40,267	-37,103	-44,333	-47,852	-33,213	-25,492	-33,947	-33,597	-26,732	-21,628	-	-
Share Based Compensation	8.2%	9,155	8,463	10,516	14,223	13,882	18,363	19,123	22,410	22,028	21,178	13,042	15,249	12,732	12,971	9,748	-	-
Cashflow From Investing	121.8%	21,994	-100,690	99,672	152,912	32,154	46,648	-57,085	25,019	-26,122	-73,862	-144,914	-39,474	136,677	32,387	-89,945	-	-
Cashflow From Financing	-96.4%	27.00	759	-143	1,196	-69.00	863	4,760	2,457	2,555	7,399	-531	393,492	884	338	35.00	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LYEL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Revenue	$ 3	$ 65
Operating expenses:
Research and development	43,174	44,630
General and administrative	13,494	19,279
Other operating income, net	(1,090)	(1,288)
Total operating expenses	55,578	62,621
Loss from operations	(55,575)	(62,556)
Interest income, net	6,819	4,497
Other income, net	1,090	1,100
Impairment of other investments	(13,001)	(10,000)
Total other loss, net	(5,092)	(4,403)
Net loss	(60,667)	(66,959)
Other comprehensive loss:
Net unrealized (loss) gain on marketable securities	(310)	3,720
Comprehensive loss	$ (60,977)	$ (63,239)
Net loss per common share, basic (in dollars per share)	$ (0.24)	$ (0.27)
Net loss per common share, diluted (in dollars per share)	$ (0.24)	$ (0.27)
Weighted-average shares used to compute net loss per common share, basic (in shares)	254,252	249,591
Weighted-average shares used to compute net loss per common share, diluted (in shares)	254,252	249,591

LYEL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 125,650	$ 145,647
Marketable securities	400,650	400,576
Prepaid expenses and other current assets	7,865	8,463
Total current assets	534,165	554,686
Restricted cash	286	284
Marketable securities, non-current	0	16,506
Other investments	19,000	32,001
Property and equipment, net	97,836	102,654
Operating lease right-of-use assets	38,695	39,663
Other non-current assets	4,238	4,235
Total assets	694,220	750,029
Current liabilities:
Accounts payable	4,895	4,817
Accrued liabilities and other current liabilities	24,914	28,126
Success payment liabilities	2,544	1,576
Total current liabilities	32,353	34,519
Operating lease liabilities, non-current	55,159	56,894
Other non-current liabilities	3,551	3,664
Total liabilities	91,063	95,077
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 500,000 shares authorized at March 31, 2024 and December 31, 2023; 254,927 and 253,958 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	25	25
Additional paid-in capital	1,666,315	1,657,133
Accumulated other comprehensive loss	(404)	(94)
Accumulated deficit	(1,062,779)	(1,002,112)
Total stockholders’ equity	603,157	654,952
Total liabilities and stockholders’ equity	$ 694,220	$ 750,029

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

CEO	Dr. Lynn Seely M.D., Ph.D.
WEBSITE	lyell.com
INDUSTRY	Biotechnology
EMPLOYEES	274

Lyell Immunopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Lyell Immunopharma, Inc.? What does LYEL stand for in stocks?

LYEL is the stock ticker symbol of Lyell Immunopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lyell Immunopharma, Inc. (LYEL)?

As of Tue May 14 2024, market cap of Lyell Immunopharma, Inc. is 645 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LYEL stock?

You can check LYEL's fair value in chart for subscribers.

What is the fair value of LYEL stock?

You can check LYEL's fair value in chart for subscribers. The fair value of Lyell Immunopharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lyell Immunopharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LYEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lyell Immunopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether LYEL is over valued or under valued. Whether Lyell Immunopharma, Inc. is cheap or expensive depends on the assumptions which impact Lyell Immunopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LYEL.

What is Lyell Immunopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, LYEL's PE ratio (Price to Earnings) is -2.82 and Price to Sales (PS) ratio is 4.96 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LYEL PE ratio will change depending on the future growth rate expectations of investors.